Marc Schneebaum

Senior Vice President and Chief Financial Officer – Avalyn Pharmaceuticals

Mr. Schneebaum brings over 30 years of experience in the biotechnology and healthcare sector and is currently Chief Financial Officer at Avalyn Pharmaceuticals. Prior to joining Avalyn, he was SVP and CFO of Madrigal Pharmaceuticals; president and CEO of Predictive Biosciences, a commercial stage cancer diagnostics company; president, CEO and a director of Sensors for Medicine and Science, a medical technology company; and SVP, Finance, BD, and CFO of Genetic Therapy, a biotechnology company acquired by Sandoz/Novartis. Mr. Schneebaum also spent time in investment banking as a VP at Alex Brown & Sons where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum has served as a director of GenVec, Inc., a publicly traded biopharmaceutical company, since 2007. Mr. Schneebaum received his degree in Business Administration from the University of Maryland and is a Certified Public Accountant (inactive).